Searchable abstracts of presentations at key conferences in endocrinology

ea0081p641 | Endocrine-Related Cancer | ECE2022

Management and long term follow up of hyperparathyroidism in multiple endocrine neoplasia type 1: single center experience

Yavropoulou Maria , Vlachou Sofia , Tsoli Marina , Fostira Florentia , Kaltsas Gregory , Kassi Eva

Background and objective: Multiple Endocrine Neoplasia type 1 (MEN 1) is an autosomal dominant disease characterized by a broad clinical spectrum. Previous multi-center studies, that analyzed large groups of patients with MEN 1 have been reported before but long term follow up data of these patients focusing exclusively on primary hyperparathyroidism (PHPT) are scarce.Patients and Methods: In this retrospective cohort study we include all patients with P...

ea0056p20 | Adrenal cortex (to include Cushing's) | ECE2018

Prevalance of primary aldosteronism in hypertensive patients: epidemiological data from a tertiary centre

Voulgaris Nikolaos , Papanastasiou Labrini , Vlachou Sofia , Kyriazi Evangelia , Tyfoxylou Ernestini , Monastirioti Nikoletta , Kapsali Chara , Charalampidou Liana , Aglaia Zachaki , Kalantzi Athanasia , Gravvanis Christos , Markou Athina , Giagourta Eirini , Kounadi Theodora , Kassi Eva , Kaltsas Gregory , Piaditis George

Introduction: Primary aldosteronism (PA) is the most common cause of endocrine hypertension. Its prevalence varies from 5-15%, which depends mainly on the cut-offs of the diagnostic tests.Aim: To estimate the prevalence of PA in patients with different stages of hypertension based on a dynamic overnight diagnostic test.Methods: One hundred ninety nine hypertensive patients were divided in 3 groups according to the stage of hyperten...

ea0056p21 | Adrenal cortex (to include Cushing's) | ECE2018

Renin: a possible novel marker for the efficacy of pharmacological treatment of primary aldosteronism

Voulgaris Nikolaos , Vlachou Sofia , Kyriazi Evangelia , Papaoikonomou Eleni , Tyfoxylou Ernestini , Monastirioti Nikoletta , Kapsali Chara , Zachaki Aglaia , Charalampidou Liana , Kounadi Theodora , Markou Athina , Papanastasiou Labrini , Giagourta Eirini , Kassi Eva , Kaltsas Gregory , Piaditis George

Introduction: Primary aldosteronism (PA) treatment is either pharmacological with aldosterone receptor antagonists (MRAs) or surgical with the resection of the responsible adenoma. The efficacy of MRAs treatment is based on the normalization of blood pressure (BP) in relation to potassium levels. However, it remains unclear whether the stimulation of renin levels during treatment could serve as an additional marker of adequate MR blockade.Aim: To investi...